CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Toevoegen aan een lijst
Financiën Chongqing Zhifei Biological Products Co., Ltd.
Aandelen
300122
CNE100000V20
Farmaceutische producten
|
Slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 24,31 CNY | -0,04% |
|
-2,21% | -7,57% |
| 09/12 | Chongqing Zhifei Biological, GSK passen voorwaarden samenwerkingsovereenkomst aan | MT |
| 05/12 | GSK breidt overeenkomst met China's Zhifei uit om samenwerking RSV-vaccin te onderzoeken | RE |
Voorlopige winst- en verliesrekening: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 10.587 | 15.190 | 30.637 | 38.264 | 52.918 | 44.131 | 49.703 | 46.122 |
| Variatie | - | 43,48% | 101,68% | 24,9% | 38,3% | -16,6% | 12,63% | -7,2% |
| EBITDA 1 | 2.910 | 4.027 | 12.394 | 9.079 | 9.700 | 4.557 | 8.469 | 8.684 |
| Variatie | - | 38,36% | 207,81% | -26,75% | 6,84% | -53,02% | 85,83% | 2,54% |
| Bedrijfsresultaat (EBIT) 1 | 2.815 | 3.894 | 11.986 | 8.758 | 9.373 | 4.217 | 11.469 | 11.155 |
| Variatie | - | 38,33% | 207,82% | -26,93% | 7,02% | -55,01% | 171,98% | -2,74% |
| Betaalde rente 1 | -74,93 | -131,4 | -21,82 | -13,8 | -47,22 | -29,75 | -24,67 | -29 |
| Resultaat voor belastingen (EBT) 1 | 2.767 | 3.853 | 11.917 | 8.718 | 9.342 | 6.991 | 10.137 | 10.044 |
| Variatie | - | 39,26% | 209,3% | -26,85% | 7,16% | -25,16% | 44,99% | -0,92% |
| Nettowinst (verlies) 1 | 2.369 | 3.300 | 10.197 | 7.539 | 8.070 | 7.511 | 9.294 | 8.636 |
| Variatie | - | 39,34% | 208,96% | -26,07% | 7,04% | -6,92% | 23,73% | -7,07% |
| Datum van publicatie | 27-02-20 | 21-02-21 | 08-02-22 | 20-03-23 | 22-04-24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Balansprognose: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | 1.234 | 1.437 | -3.502 | -617 | -3.330 | -6.172 | -15.657 | -24.003 |
| Variatie | - | 16,45% | -343,7% | -117,62% | -639,71% | -285,33% | -353,68% | -253,31% |
| Datum van publicatie | 27-02-20 | 21-02-21 | 08-02-22 | 20-03-23 | 22-04-24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte kasstroom: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 572,7 | 826,9 | 1.932 | 1.452 | 966,1 | 787,3 | 1.285 | 933,1 |
| Variatie | - | 44,37% | 133,62% | -24,81% | -33,49% | -18,51% | 63,2% | -27,38% |
| Vrije kasstroom (FCF) 1 | 794,3 | 2.670 | 6.576 | 536,6 | 8.030 | 1.986 | 6.738 | 11.072 |
| Variatie | - | 236,14% | 146,3% | -91,84% | 1.396,57% | -75,27% | 239,3% | 64,32% |
| Datum van publicatie | 27-02-20 | 21-02-21 | 08-02-22 | 20-03-23 | 22-04-24 | - | - | - |
1CNY in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 27,49% | 26,51% | 40,46% | 23,73% | 18,33% | 10,33% | 17,04% | 18,83% |
| EBIT-marge (%) | 26,59% | 25,63% | 39,12% | 22,89% | 17,71% | 9,56% | 23,08% | 24,18% |
| EBT-marge (%) | 26,13% | 25,37% | 38,9% | 22,78% | 17,65% | 15,84% | 20,4% | 21,78% |
| Nettomarge (%) | 22,37% | 21,73% | 33,28% | 19,7% | 15,25% | 17,02% | 18,7% | 18,72% |
| FCF-marge (%) | 7,5% | 17,58% | 21,46% | 1,4% | 15,18% | 4,5% | 13,56% | 24,01% |
| Vrije kasstroom/nettoresultaat (%) | 33,53% | 80,89% | 64,49% | 7,12% | 99,51% | 26,44% | 72,51% | 128,21% |
Winstgevendheid | ||||||||
| ROA | 26,66% | 25,23% | 45,08% | - | 18,29% | 16,61% | 15,12% | 14,41% |
| ROE | 47,67% | 46,28% | 77,96% | 36,13% | 29,09% | 17,54% | 21,46% | 18,01% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | 0,42x | 0,36x | - | - | - | - | - | - |
| Schuld/vrije kasstroom | 1,55x | 0,54x | - | - | - | - | - | - |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 5,41% | 5,44% | 6,31% | 3,8% | 1,83% | 1,78% | 2,59% | 2,02% |
| CAPEX / EBITDA (%) | 19,68% | 20,54% | 15,59% | 16% | 9,96% | 17,28% | 15,17% | 10,74% |
| CAPEX / FCF (%) | 72,11% | 30,97% | 29,38% | 270,69% | 12,03% | 39,64% | 19,07% | 8,43% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 0,5696 | 1,457 | 3,545 | 0,8287 | 3,748 | 5,175 | 3,3 | 3,787 |
| Variatie | - | 155,78% | 143,31% | -76,62% | 352,32% | 38,06% | -36,23% | 14,75% |
| Dividend per aandeel 1 | 0,3333 | 0,3333 | 0,4 | 0,3333 | 0,8 | 0,4695 | 0,8306 | 0,6777 |
| Variatie | - | 0% | 20% | -16,67% | 140% | -41,31% | 76,91% | -18,41% |
| Nettoactief per aandeel 1 | 2,393 | 3,433 | 7,357 | 10,1 | 13,13 | 15,06 | 18,71 | 20,81 |
| Variatie | - | 43,45% | 114,29% | 37,26% | 30% | 14,71% | 24,23% | 11,22% |
| WPA 1 | 0,9869 | 1,375 | 4,249 | 3,141 | 3,362 | 1,322 | 3,665 | 3,293 |
| Variatie | - | 39,34% | 208,95% | -26,07% | 7,04% | -60,69% | 177,27% | -10,15% |
| Aantal aandelen (in duizend) | 2.400.000 | 2.400.000 | 2.400.000 | 2.400.000 | 2.400.000 | 2.393.790 | 2.393.790 | 2.393.790 |
| Datum van publicatie | 27-02-20 | 21-02-21 | 08-02-22 | 20-03-23 | 22-04-24 | - | - | - |
1CNY
Geschatte gegevens
| 2024 * | 2025 * | |
|---|---|---|
| K/w-verhouding | 18,4x | 6,63x |
| PBR-ratio | 1,61x | 1,3x |
| EV/omzet | 1,18x | 0,86x |
| Dividendrendement | 1,93% | 3,42% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
11
Laatste slotkoers
24,31CNY
Gemiddelde koersdoel
36,39CNY
Spread / Gemiddelde doel
+49,69%
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers 300122
- Financiën Chongqing Zhifei Biological Products Co., Ltd.
